D000970

2 trials

Sponsors

McNeer Nicole, Kiyoi Hitoshi

Conditions

IDH1 gene-mutated cholangiocarcinoma IDH1, cholangiocarcinomarelapsed/refratory FLT3-mutated acute myeloid leukemia acute myeloid leukemia, relapsed/refractory, FLT3 gene mutation,

Phase 2

Open label, multicenter study of gilteritinib in sequential treatment with MEC (Mitoxantrone/ Etoposide/ Cytarabine) in patients with relapsed or refractory FLT3-mutated Acute Myeloid Leukemia

Active, not recruitingJPRN-jRCTs041200067

Kiyoi Hitoshirelapsed/refratory FLT3-mutated acute myeloid leukemia acute myeloid leukemia, relapsed/refractory, FLT3 gene mutation,

Start: 2020-12-09Target: 42Updated: 2026-06-29

JPRN-jRCT2011230033

Active, not recruitingJPRN-jRCT2011230033

McNeer NicoleIDH1 gene-mutated cholangiocarcinoma IDH1, cholangiocarcinoma

Start: 2023-09-30Target: 10Updated: 2026-06-29

Related Papers

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study

Blood2025-11-03